COVID-19 replicating RNA vaccine has robust response in nonhuman primates

A replicating RNA vaccine, formulated with a lipid-based nanoparticle emulsion, produces antibodies against the COVID-19 coronavirus in mice and primates with a single immunization. These antibodies potently neutralize the virus in young and old animals. The antibody levels induced are comparable to those in recovered COVID-19 patients. This formulation is shelf-stable, with mass-production and distribution advantages.

Chinese phase 2 trial finds COVID-19 vaccine is safe and induces an immune response

A phase 2 randomized controlled trial of a recombinant adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine) was conducted in China in April 2020 and involved more than 500 people. The primary objective of the study was to evaluate the immune response and safety of the vaccine, and to determine the most suitable dose for a phase 3 trial. Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection.